(439 days)
The Intermedics Models 430-07 and 432-03 Endocardial Pacing Leads.
Not Found
No
The document describes a passive pacing lead and does not mention any computational or adaptive capabilities that would suggest AI/ML.
Yes
The device is an endocardial pacing lead designed to deliver electrical impulses to the heart to treat conditions like sick sinus syndrome and heart block, which directly addresses disease symptoms.
No.
Explanation: The device is an endocardial pacing lead designed to deliver electrical impulses for long-term cardiac pacing and to sense cardiac electrical activity, not to diagnose a condition.
No
The device is described as endocardial pacing leads, which are physical components designed for implantation and electrical stimulation of the heart. The description details the lead body, electrodes, and fixation mechanism, all of which are hardware.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for "long-term cardiac pacing" by being implanted within the body and interacting directly with the heart.
- Device Description: The description details an implantable lead that carries electrical impulses to and from the heart.
- IVD Definition: In Vitro Diagnostics are devices used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information about a person's health. This device does not perform such testing on specimens.
The device described is an implantable medical device used for therapeutic purposes (pacing the heart), not for diagnostic testing of samples outside the body.
N/A
Intended Use / Indications for Use
The Intermedics leads which are the subject of this 510(k) Notification are endocardial pacing leads designed for use with implantable pulse generators for long-term cardiac pacing, This indication is identical to the indication for use of the legally marketed predicate devices, the Intermedics Models 430-07 and 432-03 Endocardial Pacing Leads.
The indications for ventricular pacing include, but are not limited to: sick sinus syndrome, sinus bradycardia, complete heart block, symptomatic second-degree heart block, and certain conditions of asymptomatic second-degree block. In the presence of normal atrioventricular (A-V) conduction, the indications for atrial pacing include, but are not limited to: sinus arrest, sick sinus syndrome, sinus bradycardia and conditions requiring increased cardiac efficiency, enhanced cardiac output or the overdrive of certain cardiac arrhythmias. In the absence of normal A-V conduction, an atrial lead may be used with a ventricular lead in a dual-chamber pacing system to restore A-V synchrony.
Product codes
Not Found
Device Description
The Intermedics Model 430-07, 431-07, 432-03, and 433-03 Endocardial Pacing Leads are designed for use with implantable cardiac pulse generators for long-term cardiac pacing. Passed transvenously through the cephalic, subclavian, or jugular vein (external or internal), the tip electrode (cathode) is positioned at the endocardial surface to permit contact with the heart. The tip fixation mechanism consists of four silicone rubber tines. The lead body, which consists of insulated conductor coils, carries electrical impulses from the heart to the pulse generator, resulting in sensing. The lead body also carries impulses from the pulse generator to the endocardial surface, causing cardiac depolarization (pacing), The proximal end of the lead is connected to the header of the implanted pulse generator.
The electrodes of the Intermedics Model 430-07, 431-07, 432-03, and 433-03 Endocardial Pacing Leads are made of titanium coated with inidium oxide (IROX™). Clinical trials with the Models 430-07 and 432-03 IROX endocardial pacing leads through twelve months demonstrated low threshold performance: 1.5 volts at or below 0.38 millisecond pulse width, with 97.5% confidence
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Ventricular (for Models 430-07 and 431-07 leads), Atrial (for Models 432-03 and 433-03 leads). More generally, endocardial surface of the heart.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Animal Study
- Study Type: Long-term animal study
- Sample Size: 24 leads implanted in 12 dogs
- Data Source: Intermedics Endocardial Pacing Leads with iridium oxide-coated titanium tip electrodes. Leads used were Biopore™ Leads (carbon-coated porous titanium electrode), IROX™ Leads (indium oxide-coated titanium electrode), and IROXTM Leads (iridium oxide-coated titanium electrode layered with a thin coating of polyethylene glycol (PEG)).
- Key Results: Stimulation thresholds were measured at regular intervals for 24 weeks. The IROX-PEG stimulation thresholds rose only 0.23 volts from implant to the chronic period (after week 6), and were significantly lower than those of Biopore and IROX. Low acute values were observed for all leads, but the IROX-PEG electrode demonstrated lower subchronic, peak and chronic values, with the mean pacing threshold less than 0.6 millisecond pulse width at 24 weeks. The data from this study establish the low threshold characteristics of the IROX-PEG electrode.
Clinical Study
- Study Type: Clinical performance data gathering
- Sample Size: Not explicitly stated, but performed with Models 430-07 and 432-03 Endocardial Pacing Leads.
- Data Source: Models 430-07 and 432-03 Endocardial Pacing Leads. Pacing threshold data were reported at implant, two weeks, four weeks, six weeks, three months, six months and twelve months.
- Key Results: The data showed a mean pacing threshold of 0.32 millisecond in the ventricle and 0.35 millisecond in the atrium at 1.5 volts at the two-week follow-up point; this threshold gradually decreased to a mean value of 0.26 millisecond in both chambers at the six-month follow-up visit. Statistical analysis demonstrated that the dependence of capturing pulse width on pulse amplitude remains invariant with respect to time elapsed from implant. An upper confidence bound of 97.5% on the capturing pulse width was computed to be at or below 0.38 millisecond at a pulse amplitude of 1.5 volts. The results establish the low threshold performance of the Models 430-07 and 432-03 Endocardial Pacing Leads on both an acute and a chronic basis.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
- Mean stimulation threshold (acute and chronic): Less than or equal to 0.38 millisecond at a pulse amplitude of 1.5 volts, with a 97.5 percent confidence limit.
- Pacing threshold at 2 weeks: Mean 0.32 millisecond in ventricle, 0.35 millisecond in atrium at 1.5 volts.
- Pacing threshold at 6 months: Mean 0.26 millisecond in both chambers.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
The Intermedics Models 430-07 and 432-03 Endocardial Pacing Leads.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3680 Cardiovascular permanent or temporary pacemaker electrode.
(a)
Temporary pacemaker electrode —(1)Identification. A temporary pacemaker electrode is a device consisting of flexible insulated electrical conductors with one end connected to anexternal pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator.(2)
Classification. Class II (performance standards).(b)
Permanent pacemaker electrode —(1)Identification. A permanent pacemaker electrode is a device consisting of flexible insulated electrical conductors with one end connected to an implantable pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator.(2)
Classification. Class III (premarket approval).(c)
Date PMA or notice of completion of PDP is required. A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before October 4, 2012, for any permanent pacemaker electrode device that was in commercial distribution before May 28, 1976, or that has, on or before October 4, 2012, been found to be substantially equivalent to any permanent pacemaker electrode device that was in commercial distribution before May 28, 1976. Any other pacemaker repair or replacement material device shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/4 description: The image shows the logo for Intermedics Inc., a company of Sulzer Medica. The logo features a stylized graphic to the left of the company name, with the tagline "A company of SULZER medica" underneath. The text is in a bold, sans-serif font, and the overall design is simple and professional.
DEC 16 1996
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR § 807.92.
Submitter's Name: Intermedics, Inc. 4000 Technology Drive Angleton, TX 77515 USA Telephone: (409) 848-4525 Contact Person: Alan D. Totah, Director of Domestic Regulatory Affairs
Date of Summary: December 6, 1996
Device Names: Model 430-07 Endocardial Pacing Lead Model 431-07 Endocardial Pacing Lead Model 432-03 Endocardial Pacing Lead Model 433-03 Endocardial Pacing Lead
Legally Marketed Devices To Which Equivalence Is Claimed: The Intermedics Models 430-07 and 432-03 Endocardial Pacing Leads.
The Intermedics lead models which are the subject of this 510(k) Notification are legally marketed devices. This 510(k) Notification is submitted to provide data and evidence to support labeling claims concerning the low threshold performance of the indium oxide-coated (IROXTM) titanium tip electrode. In this submission, the Models 430-07 and 432-03 Endocardial Pacing Leads are considered the legally marketed predicate devices since these models were employed in the clinical study which yielded the low threshold data in humans. Since the IROX tip electrode is identical among all lead models in design, materials and construction, the clinical data gathered on the performance of the Model 430-07 and 432-03 Leads are directly applicable to the performance of the other lead models, and the claims concerning low threshold performance are therefore made for all lead models.
New Performance Claim: This 510(k) Notification is submitted to provide data and evidence to support the following labeling claim concerning the low threshold performance of the iridium oxide-coated (IROX) titanium tip electrode:
The mean stimulation threshold, both acute and chronic, is equal to or less than 0.38 millisecond at a pulse amplitude of 1.5 volts, with a 97.5 percent confidence limit.
Device Description: The Intermedics Model 430-07, 431-07, 432-03, and 433-03 Endocardial Pacing Leads are designed for use with implantable cardiac pulse generators for long-term cardiac pacing. Passed transvenously through the cephalic, subclavian, or jugular
1
vein (external or internal), the tip electrode (cathode) is positioned at the endocardial surface to permit contact with the heart. The tip fixation mechanism consists of four silicone rubber tines. The lead body, which consists of insulated conductor coils, carries electrical impulses from the heart to the pulse generator, resulting in sensing. The lead body also carries impulses from the pulse generator to the endocardial surface, causing cardiac depolarization (pacing), The proximal end of the lead is connected to the header of the implanted pulse generator.
The electrodes of the Intermedics Model 430-07, 431-07, 432-03, and 433-03 Endocardial Pacing Leads are made of titanium coated with inidium oxide (IROX™). Clinical trials with the Models 430-07 and 432-03 IROX endocardial pacing leads through twelve months demonstrated low threshold performance: 1.5 volts at or below 0.38 millisecond pulse width, with 97.5% confidence
Intended Use: The Intermedics leads which are the subject of this 510(k) Notification are endocardial pacing leads designed for use with implantable pulse generators for long-term cardiac pacing, This indication is identical to the indication for use of the legally marketed predicate devices, the Intermedics Models 430-07 and 432-03 Endocardial Pacing Leads.
The indications for ventricular pacing include, but are not limited to: sick sinus syndrome, sinus bradycardia, complete heart block, symptomatic second-degree heart block, and certain conditions of asymptomatic second-degree block. In the presence of normal atrioventricular (A-V) conduction, the indications for atrial pacing include, but are not limited to: sinus arrest, sick sinus syndrome, sinus bradycardia and conditions requiring increased cardiac efficiency, enhanced cardiac output or the overdrive of certain cardiac arrhythmias. In the absence of normal A-V conduction, an atrial lead may be used with a ventricular lead in a dual-chamber pacing system to restore A-V synchrony.
Descriptive Summary Of Technological Characteristics And Those Of Predicate Devices: Following is a summary of the technological characteristics of the Models 430-07 and 432-03 Endocardial Pacing Leads (predicate devices) and those of the other lead models which are the subject of this 510(k) Notification:
- The Model 430-07 is a bipolar lead, designed for use in the ventricle. .
- The Model 431-07 is a unipolar lead, designed for use in the ventricle. �
- The Model 432-03 is a bipolar lead, designed for use in the atrium. ●
- The Model 433-03 is a unipolar lead, designed for use in the atrium. .
All these leads have the same tip electrode, identical in design (slotted blunt tip), materials (titanium coated with iridium oxide), and construction. The differences among the lead models do not pertain to new indications for use nor to new technological characteristics. These differences pertain only to the polarity of the lead and to the heart chamber in which the lead is implanted. The differences among the lead models do not affect the safety and effectiveness of the devices, nor do they affect the performance claim which is the subject of this 510(k) Notification.
2
Performance Data: Animal and human clinical performance data, acute and chronic, have been gathered on Intermedics Endocardial Pacing Leads with iridium oxide-coated titanium tip electrodes.
Animal Study
In order to evaluate the electrical performance of new electrode technologies, Intermedics conducted a long-term animal study of endocardial leads. Twenty-four leads were implanted in twelve dogs. All leads were unipolar, 5 French lead body, polyurethane insulated tined leads. Eight of each of the following leads were used in the study
- Biopore™ Leads ("Biopore"), with a carbon-coated porous titanium electrode;
- IROX™ Leads ("IROX"), with an indium oxide-coated titanium electrode; and
- . IROXTM Leads ("IROX-PEG"), with an iridium oxide-coated titanium electrode layered with a thin coating of polyethylene glycol (PEG).
Stimulation thresholds were measured at regular intervals for 24 weeks. The IROX-PEG stimulation thresholds rose only 0.23 volts from implant to the chronic period (after week 6), and were significantly lower than those of Biopore and IROX. Low acute values were observed for all leads, but the IROX-PEG electrode demonstrated lower subchronic, peak and chronic values, with the mean pacing threshold less than 0.6 millisecond pulse width at 24 weeks. The data from this study establish the low threshold characteristics of the IROX-PEG electrode
Clinical Study
Clinical performance data have been gathered on the Models 430-07 and 432-03 Endocardial Pacing Leads to support the performance claim of low acute and chronic stimulation threshold. Pacing threshold data were reported at implant, two weeks, four weeks, six weeks, three months, six months and twelve months. The data showed a mean pacing threshold of 0.32 millisecond in the ventricle and 0.35 millisecond in the atrium at 1.5 volts at the twoweek follow-up point; this threshold gradually decreased to a mean value of 0.26 millisecond in both chambers at the six-month follow-up visit. Statistical analysis demonstrated that the dependence of capturing pulse width on pulse amplitude remains invariant with respect to time elapsed from implant. An upper confidence bound of 97.5% on the capturing pulse width was computed to be at or below 0.38 millisecond at a pulse amplitude of 1.5 volts.
The results of the clinical study establish the low threshold performance of the Models 430-07 and 432-03 Endocardial Pacing Leads on both an acute and a chronic basis, and support the low threshold labeling claim proposed by Intermedics.